Can I read Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer on EtoBox?

Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer by Yulong Chen; Bo Yan; Feng Xu; Zhenzhen Hui; Gang Zhao; Jie Liu; Huan Zhang; Ziqing Zeng; Ran Zhang; Mariano Provencio; Xiubao Ren; Jian You is a Medicine article available to read on EtoBox.

What is Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer about?

## Background A small proportion of patients with non-small cell lung cancer (NSCLC) experience objective clinical benefit after neoadjuvant programmed cell death 1 (PD-1) blockade. A neoadjuvant therapeutic regimen combining immune checkpoint blockade with chemotherapy might improve the treatment effect, but such a regimen has not been tested in patients with resectable stage IIIA/IIIB NSCLC. ## Methods A retrospective study of 35 patients with resectable stage IIIA and IIIB NSCLC who were treated with neoadjuvant chemoimmunotherapy (NCIO) was performed. Patients were evaluated for pathological complete response (pCR), major pathologic response (MPR), safety, and feasibility. The correlations of pathologic response with various clinical factors were studied to identify predictors of pathological response. ## Results NCIO was associated with few immediate adverse events. NCIO did not delay planned surgery and led to a pCR rate of 51.43% and an MPR rate of 74.29% for the primary tumor. No association was observed between programmed death-ligand 1 (PD-L1) expression before NCIO and the pathologic response (Pearson’s r=−0.071; P=0.685). However, a significant difference was observed i

Who reads Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer?

Author

Yulong Chen; Bo Yan; Feng Xu; Zhenzhen Hui; Gang Zhao; Jie Liu; Huan Zhang; Ziqing Zeng; Ran Zhang; Mariano Provencio; Xiubao Ren; Jian You

Publisher

AME Publishing Company

Published

2021

Language

EN

Field

Medicine (Health Sciences)